This document is an investor presentation for Innovative Drug Delivery Solutions that discusses the company's forward-looking statements and drug delivery platforms. It summarizes the market opportunities for oral thin films, highlights the company's product pipeline including approved products and products in development, and describes their strategy to focus on developing products using oral films that provide benefits to patients. Financial results for 2015 and Q1 2016 are also presented, which demonstrate record results and an improving financial position as the company executes its strategy.

1. 0
Investor Presentation
June 17, 2016
Innovative Drug Delivery Solutions

2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements
on our current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"
"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Forward-looking statements
include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and
Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax
rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from
time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities
Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
1
Forward Looking Statements

3. 2
2
2
Oral Thin Films
Oral Thin Films Provide
Significant Market Opportunities
for Improving Drug Delivery
• IntelGenx CEO co-developer of the
Listerine breath strips
• Oral films ideal for elderly, children,
patients who have difficulty swallowing
traditional tablets
• Quicker action to relieve symptoms

4. 3
3
Strong Demographics for Oral Films
Many patient applications are compatible
with oral film characteristics
• Those who have difficult swallowing large pills:
pediatric, geriatric, or dysphagic
• North Americans over 65 will grow from 54MM to 85MM
over the next 15 years
• Patients who suffer gastrointestinal (GI) side effects
from their medication
• Normal patients who would prefer a more discrete
or pleasant administration of the drug

5. 4
4
Making Approved Drugs Better
Rapidly disintegrating film improving
drug performance and easing administration
without the need for water
Films
VersaFilm™
Tablets
Controlled-release tablets for oral
absorption over an extended time period
IntelGenx Drug Delivery Technology Platforms
VersaTab™ AdVersa™

6. 5
Indication
Partnering
Availability
Formulation
Development
Pilot
Study
Pivotal Study Filing Launch
Films
$17B
Migraine – Rizaport TM - Rizatriptan Available ex- ES
Erectile Dysfunction - Tadalafil Available
Opioid Dependence Par
Pharmaceuticals
Schizophrenia - Loxapine Available
Undisclosed Term Sheet
Pain Term Sheet
Central Nervous System (CNS) Term Sheet
CNS - Montelukast Available
Respiratory (Cough & Cold) In Discussion
Cardiovascular In Discussion
Tablets
$1.7B
Major Depressive Disorder –
Forfivo XL®
Bupropion
Edgemont
Pharmaceuticals
Available ex-USA
Hypertension - Metoprolol Available
Pain - Dronabinol Available
A Robust Product Pipeline to Address
Significant Market Opportunities
5

7. 6
Forfivo XL
6
• High dose version of Wellbutrin XL®
• Only approved, once-daily, bupropion
HCl 450mg dose in a single tablet
• Launched commercially October 2013
in partnership with Edgemont
Pharmaceuticals
• Q1 2016 net sales grew 39% compared
to Q1 2015, with net sales at $2.5 million
($4.9 million gross)
First 450mg tablet approved by
FDA for major depressive disorder
$0.00
$500.00
$1,000.00
$1,500.00
$2,000.00
$2,500.00
$3,000.00
$3,500.00
1Q15 2Q15 3Q15 4Q15 1Q16
Forfivo XL Net Sales ($,000s)

8. 7
7
For Migraines
Leverages VersaFilm™ Technology
• European Mktg Approval – November 2015
• Filed 505(b)(2) NDA - March 2013 for USA
• Co-development partnership with
RedHill Biopharma
• Negotiations with commercialization partner ongoing
• Patent granted in April 2016 protecting Rizaport
• Term Sheet signed March 2016 with
Grupo Juste for Spain & additional territories
• Planned USA submission to FDA Q4/2016
• Expected USA launch Q2/2017

9. 8
For Erectile Dysfunction
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for ED
• Containing tadalafil (Cialis® - Eli Lilly),
a major molecule in the ED market
• Demonstrated bioequivalence to Cialis®
• Orally disintegrating films without need
for water provide unprecedented patient
convenience and a discrete dosing
alternative
• 505(b)(2) USA NDA submission in
Q4/2016
• Expected USA launch Q4/2017
8

10. 9
Strategy Update
9

11. 10
Strengthened Management Team
Over 20 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma
industry experience
• Member of the Canadian
Chartered Professional
Accountants and the
Canadian Institute of
Chartered Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx
Trilayer Technology
• 15 years experience in product
development and technology
transfer
Robert Bechard, M. Sc.
VP, Corporate Development
• 20+ years experience in
biopharmaceutical and
venture capital
• Managing Partner of
Lifescience venture fund at
RBC Capital
• Director on 25 lifescience
boards
Edward Miller, B. Comm
Director, Investor Relations
• 15 years experience in investor
relations
• 10 + years experience in
pharmaceutical / biotech
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine
breath strips
• 30+ years drug delivery /
pharma experience
• Holds over 40 patents in drug
delivery and numerous
scientific publications
10
Dana Matzen, Ph.D.
VP, Business Development
• 15 years experience in
pharmaceutical product
licensing
• Former Director,
BD at Paladin Labs
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical
manufacturing, quality
management, product
development
• Held executive positions with
several Canadian and US
companies

12. 11
11
Completion of Construction
of Manufacturing Facility
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• Facility to be fully operational by Q1 2017
• High capacity manufacturing and
packaging equipment
• Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS
We have built a state-of-the-art
oral film development and manufacturing facility

13. 12
12
We are Now Poised for Success
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide tangible patient benefits
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• Lifecycle management
• Repurpose existing drugs for new indications using oral films
• First-to-file generic drug where high technology barriers to
entry exist in reproducing branded films

14. 13
13
What Makes IntelGenx the Best in Oral Films
1. History
• Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
• Strong in applying biopharmaceutical aspects to formulation development
• Top quality scientists: highly creative, focused on problem solving & innovative approaches
• Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Competitive Manufacturing Capabilities
• First in Canada
• New state-of-the-art manufacturing facility
• Offer one-stop-shopping to our partners with lean operations keeping costs down
• Customized manufacturing equipment

15. 14
Financial Results
14

16. 15
Record Results in 2015 Demonstrates
Strong Execution of Strategy
Revenue ($M)
0.82
0.63
5.1
1.7
0
1
2
3
4
5
6
Q1 2016 Q1 2015 2015 Full Year 2014 Full Year
Revenue
$M
15

17. 16
Net Comprehensive Income & Adjusted EBITDA ($M)
-0.71
-0.38
0.8
-2.2
-0.56
0.05
1.7
-1.6
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
Q1 2016 Q1 2015 2015 Full Year 2014 Full Year
Net Income Adjusted EBITDA
$M
Transforming IntelGenx for a Strong Future
16

18. 17
Conclusion
17

19. 18
18
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry

20. 19
19
Thank You
www.IntelGenx.com